Bogdan J Wlodarczyk1, Krystal Ogle1, Linda Ying Lin1, Meir Bialer2, Richard H Finnell1,3. 1. Department of Nutritional Sciences, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA. 2. School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. 3. Department of Chemistry and Biochemistry, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, TX, USA.
Abstract
OBJECTIVES: Based on the recent findings from animal studies, it has been proposed that the therapeutic use of valnoctamide, an anxiolytic drug developed in the early 1960s, be extended to treat other neurological disorders such as epilepsy and bipolar disease. Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system. METHODS: Pregnant dams were treated with the aforementioned three drugs at the dose levels calculated as an equal proportion of the respective LD50 values of these drugs. The main reproductive indices examined included the numbers of implantations and resorptions, viable and dead fetuses, and fetal gross, visceral and skeletal abnormalities. RESULTS: The outcomes of the present study indicated that olanzapine was the most teratogenic of the three drugs, inducing maternal-, embryo-, and fetotoxicity. Risperidone also exerted a significant prenatal toxicity, but its adverse effect was less pronounced than that induced by olanzapine. Valnoctamide did not show any teratogenic effect, even when used in relatively higher dosages than olanzapine and risperidone. The observed increased skeletal abnormalities in one of the valnoctamide treatment groups were nonspecific and, as such, signaled a modest developmental delay rather than an indication that the compound could induce structural malformations. CONCLUSIONS: Under our experimental conditions, valnoctamide demonstrated the lowest prenatal toxicity of the three tested drugs.
OBJECTIVES: Based on the recent findings from animal studies, it has been proposed that the therapeutic use of valnoctamide, an anxiolytic drug developed in the early 1960s, be extended to treat other neurological disorders such as epilepsy and bipolar disease. Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system. METHODS: Pregnant dams were treated with the aforementioned three drugs at the dose levels calculated as an equal proportion of the respective LD50 values of these drugs. The main reproductive indices examined included the numbers of implantations and resorptions, viable and dead fetuses, and fetal gross, visceral and skeletal abnormalities. RESULTS: The outcomes of the present study indicated that olanzapine was the most teratogenic of the three drugs, inducing maternal-, embryo-, and fetotoxicity. Risperidone also exerted a significant prenatal toxicity, but its adverse effect was less pronounced than that induced by olanzapine. Valnoctamide did not show any teratogenic effect, even when used in relatively higher dosages than olanzapine and risperidone. The observed increased skeletal abnormalities in one of the valnoctamide treatment groups were nonspecific and, as such, signaled a modest developmental delay rather than an indication that the compound could induce structural malformations. CONCLUSIONS: Under our experimental conditions, valnoctamide demonstrated the lowest prenatal toxicity of the three tested drugs.
Authors: J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig Journal: J Neurol Neurosurg Psychiatry Date: 2005-09-12 Impact factor: 10.154
Authors: Elena Menegola; Francesca Di Renzo; Maria L Broccia; Michela Prudenziati; Saverio Minucci; Valentina Massa; Erminio Giavini Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2005-10
Authors: Cynthia L Harden; Kimford J Meador; Page B Pennell; W Allen Hauser; Gary S Gronseth; Jacqueline A French; Samuel Wiebe; David Thurman; Barbara S Koppel; Peter W Kaplan; Julian N Robinson; Jennifer Hopp; Tricia Y Ting; Barry Gidal; Collin A Hovinga; Andrew N Wilner; Blanca Vazquez; Lewis Holmes; Allan Krumholz; Richard Finnell; Deborah Hirtz; Claire Le Guen Journal: Epilepsia Date: 2009-05 Impact factor: 5.864
Authors: Kimford J Meador; Gus A Baker; Nancy Browning; Jill Clayton-Smith; Deborah T Combs-Cantrell; Morris Cohen; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring Journal: N Engl J Med Date: 2009-04-16 Impact factor: 91.245
Authors: Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol Journal: J Neurosci Date: 2017-06-19 Impact factor: 6.167
Authors: Sara Ornaghi; John N Davis; Kelly L Gorres; George Miller; Michael J Paidas; Anthony N van den Pol Journal: Virology Date: 2016-09-19 Impact factor: 3.616
Authors: Alexei P Kudin; Hafiz Mawasi; Arik Eisenkraft; Christian E Elger; Meir Bialer; Wolfram S Kunz Journal: Int J Mol Sci Date: 2017-09-06 Impact factor: 5.923